• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

瑞德西韦治疗新型冠状病毒肺炎相关的显著窦性心动过缓：1例病例及文献综述

Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review.

作者信息

Gubitosa James C, Kakar Parul, Gerula Christine, Nossa Hernando, Finkel Diana, Wong Kristin, Khatri Megna, Ali Hasan

机构信息

Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey.

Department of Cardiology, Rutgers New Jersey Medical School, Newark, New Jersey.

出版信息

JACC Case Rep. 2020 Nov 18;2(14):2260-2264. doi: 10.1016/j.jaccas.2020.08.025. Epub 2020 Oct 28.

DOI:10.1016/j.jaccas.2020.08.025
PMID:33163977
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7598346/
Abstract

Remdesivir has seen extensive use during the coronavirus disease-2019 pandemic given its clinically proven efficacy against severe acute respiratory syndrome coronavirus type 2. There has been little cited regarding adverse effects. Here we present the case of a patient with marked sinus bradycardia that began acutely on initiation of remdesivir and resolved almost immediately on cessation of the drug. ().

摘要

鉴于瑞德西韦对严重急性呼吸综合征冠状病毒2型具有临床验证的疗效，在2019年冠状病毒病大流行期间已被广泛使用。关于其不良反应的报道很少。在此，我们报告一例患者，在开始使用瑞德西韦后急性出现显著窦性心动过缓，停药后几乎立即缓解。（）

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f22/8299849/0d5eeae38992/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f22/8299849/cd66c98c1771/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f22/8299849/75b4948bb2f5/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f22/8299849/014902556da5/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f22/8299849/0d5eeae38992/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f22/8299849/cd66c98c1771/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f22/8299849/75b4948bb2f5/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f22/8299849/014902556da5/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f22/8299849/0d5eeae38992/gr3.jpg

相似文献

1
Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review.瑞德西韦治疗新型冠状病毒肺炎相关的显著窦性心动过缓：1例病例及文献综述
JACC Case Rep. 2020 Nov 18;2(14):2260-2264. doi: 10.1016/j.jaccas.2020.08.025. Epub 2020 Oct 28.
2
Remdesivir-Induced Marked Sinus Bradycardia in COVID-19.瑞德西韦在新冠病毒疾病中引发显著窦性心动过缓
Cureus. 2022 Jul 25;14(7):e27249. doi: 10.7759/cureus.27249. eCollection 2022 Jul.
3
Complete heart block associated with Remdesivir in COVID-19: a case report.新型冠状病毒肺炎中瑞德西韦相关的完全性心脏传导阻滞：一例报告
Eur Heart J Case Rep. 2021 Jul 1;5(7):ytab200. doi: 10.1093/ehjcr/ytab200. eCollection 2021 Jul.
4
Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19: A Case Report and Literature Review.瑞德西韦治疗新型冠状病毒肺炎相关窦性心动过缓：一例报告及文献综述
J Cardiovasc Dev Dis. 2021 Feb 12;8(2):18. doi: 10.3390/jcdd8020018.
5
Remdesivir-Induced Extreme Sinus Bradycardia in COVID-19.瑞德西韦导致新型冠状病毒肺炎患者出现严重窦性心动过缓
Cureus. 2022 Jul 26;14(7):e27307. doi: 10.7759/cureus.27307. eCollection 2022 Jul.
6
Remdesivir-Associated Sinus Arrest in COVID-19: A Potential Indication for Close Cardiac Monitoring.瑞德西韦相关的新型冠状病毒肺炎窦性停搏：心脏密切监测的潜在指征
Cureus. 2022 Feb 17;14(2):e22328. doi: 10.7759/cureus.22328. eCollection 2022 Feb.
7
Heart Brake: An Unusual Cardiac Manifestation of COVID-19.心脏骤停：新型冠状病毒肺炎一种不寻常的心脏表现
JACC Case Rep. 2020 Jul 15;2(9):1252-1255. doi: 10.1016/j.jaccas.2020.04.026. Epub 2020 May 3.
8
Remdesivir associated sinus bradycardia in patients with COVID-19: A prospective longitudinal study.瑞德西韦与新型冠状病毒肺炎患者窦性心动过缓的相关性：一项前瞻性纵向研究。
Front Pharmacol. 2023 Jan 17;13:1107198. doi: 10.3389/fphar.2022.1107198. eCollection 2022.
9
Direct Wenckebach periods in the left bundle branch during bradycardia-dependent left bundle branch block in a patient with sick sinus syndrome.病态窦房结综合征患者在心动过缓依赖性左束支传导阻滞时左束支出现的直接文氏周期。
J Electrocardiol. 1980;13(3):291-6. doi: 10.1016/s0022-0736(80)80034-3.
10
Remdesivir therapy causing bradycardia in COVID-19 patients: Two case reports.瑞德西韦治疗导致新冠肺炎患者心动过缓：两例病例报告。
IDCases. 2021;26:e01254. doi: 10.1016/j.idcr.2021.e01254. Epub 2021 Aug 12.

引用本文的文献

1
COVID-19 and Cardiac Arrhythmias: Lesson Learned and Dilemmas.新冠病毒肺炎与心律失常：经验教训与困境
J Clin Med. 2024 Nov 29;13(23):7259. doi: 10.3390/jcm13237259.
2
Electrophysiological Profile of Different Antiviral Therapies in a Rabbit Whole-Heart Model.不同抗病毒疗法在兔整体心脏模型中的电生理特征。
Cardiovasc Toxicol. 2024 Jul;24(7):656-666. doi: 10.1007/s12012-024-09872-3. Epub 2024 Jun 8.
3
Remdesivir-Induced Bradycardia and Mortality in SARS-CoV-2 Infection, Potential Risk Factors Assessment: A Systematic Review and Meta-Analysis.

本文引用的文献

1
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.瑞德西韦治疗新冠病毒病-初步报告。回复。
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
2
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
3
Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
瑞德西韦在新冠病毒感染中导致的心动过缓和死亡率：潜在风险因素评估——一项系统评价与荟萃分析
J Clin Med. 2023 Dec 5;12(24):7518. doi: 10.3390/jcm12247518.
4
QTc Prolongation to Predict Mortality in Patients Admitted with COVID-19 Infection: An Observational Study.QTc 延长预测 COVID-19 感染住院患者的死亡率：一项观察性研究。
Curr Vasc Pharmacol. 2024;22(2):106-121. doi: 10.2174/0115701611250248231114114557.
5
Adverse Events in Pregnant Patients Treated with Coronavirus Disease 2019 Therapeutics.妊娠期新型冠状病毒 2019 治疗药物的不良反应。
J Med Toxicol. 2023 Oct;19(4):381-388. doi: 10.1007/s13181-023-00961-3. Epub 2023 Aug 15.
6
Bradycardia and Outcomes in COVID-19 Patients on Remdesivir: A Multicenter Retrospective Study.接受瑞德西韦治疗的COVID-19患者的心动过缓和预后：一项多中心回顾性研究。
Cardiol Res. 2023 Jun;14(3):192-200. doi: 10.14740/cr1493. Epub 2023 May 26.
7
Remdesivir-associated bradycardia in COVID-19: a rapid review protocol.瑞德西韦相关 COVID-19 患者的心动过缓：快速综述方案。
BMJ Open. 2023 May 31;13(5):e068564. doi: 10.1136/bmjopen-2022-068564.
8
Remdesivir-induced conduction abnormalities: A molecular model-based explanation.瑞德西韦致传导异常：基于分子模型的解释。
J Pharm Pharm Sci. 2023 Feb 13;26:11208. doi: 10.3389/jpps.2023.11208. eCollection 2023.
9
Complicated appendicitis, acute pancreatitis, pleural effusion, and sinus bradycardia in a COVID-19 patient.一名新冠肺炎患者出现复杂性阑尾炎、急性胰腺炎、胸腔积液和窦性心动过缓。
Clin Case Rep. 2023 Mar 8;11(3):e7077. doi: 10.1002/ccr3.7077. eCollection 2023 Mar.
10
Remdesivir-Induced Bradycardia.瑞德西韦导致的心动过缓。
South Med J. 2023 Mar;116(3):317-320. doi: 10.14423/SMJ.0000000000001519.
瑞德西韦是一种直接作用的抗病毒药物，能高效抑制严重急性呼吸综合征冠状病毒 2 的 RNA 依赖性 RNA 聚合酶。
J Biol Chem. 2020 May 15;295(20):6785-6797. doi: 10.1074/jbc.RA120.013679. Epub 2020 Apr 13.
4
Compassionate Use of Remdesivir for Patients with Severe Covid-19.瑞德西韦在治疗重症 COVID-19 患者中的同情使用。
N Engl J Med. 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10.
5
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.埃博拉病毒病治疗的随机、对照试验。
N Engl J Med. 2019 Dec 12;381(24):2293-2303. doi: 10.1056/NEJMoa1910993. Epub 2019 Nov 27.
6
Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir.瑞德西韦抑制埃博拉病毒 RNA 依赖的 RNA 聚合酶的机制。
Viruses. 2019 Apr 4;11(4):326. doi: 10.3390/v11040326.
7
Drug-induced mitochondrial dysfunction and cardiotoxicity.药物诱导的线粒体功能障碍和心脏毒性。
Am J Physiol Heart Circ Physiol. 2015 Nov;309(9):H1453-67. doi: 10.1152/ajpheart.00554.2015. Epub 2015 Sep 18.